reports
Believe S A: 1 director
A director at Believe S A sold 11,684,314 shares at 15.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Heal...
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference BOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced that Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 14, 2024, at 3:35 p.m. EDT. The presentation will be webcast live on the . Additionally, a replay will be available on the website after its completion. About ...
Harmony Biosciences Reports Strong First Quarter Financial Results and...
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward Pediatric Exclusivity to Extend WAKIX Exclusivity to September 2030: Pediatric Narcolepsy sNDA PDUFA Date of June 21, 2024; PW...
Clearside Biomedical to Report First Quarter 2024 Financial Results an...
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the result...
Inari Amertron Bhd: 1 director
A director at Inari Amertron Bhd sold 2,000,000 shares at 0.000MYR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
AirSculpt Technologies Announces First Quarter 2024 Earnings Release D...
AirSculpt Technologies Announces First Quarter 2024 Earnings Release Date and Conference Call MIAMI BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced it will report first quarter 2024 financial results before market open on Friday, May 10, 2024, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference...
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results ...
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets. Management will conduct a conference call at 5:00 p.m. ET on the same day to provide a corporate update. The confere...
PyroGenesis Kicks Off New European Distribution Strategy with Contract...
PyroGenesis Kicks Off New European Distribution Strategy with Contract to Supply Spanish Aerospace Entity with Titanium Metal Powder MONTREAL, April 30, 2024 (GLOBE NEWSWIRE) -- PyroGenesis Canada Inc. () (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to announce the signing of an initial contract with an aerospace entity in Spain for the sal...
CECO Environmental Reports First Quarter 2024 Results
CECO Environmental Reports First Quarter 2024 Results Reports Record First Quarter Revenue and Gross Margins, Near Record BacklogReaffirms Full Year 2024 Guidance DALLAS, April 30, 2024 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO) ("CECO"), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today reported its financial results for the first quarter results of 2024. First Quarter Summary(1) Orders of $145.3 millionBacklog of $389.5 million, up 9 percentRevenue of $126.3 million...
KKR’s Henry McVey Says Insurance CIOs Plan to Increase Allocations to ...
NEW YORK--(BUSINESS WIRE)-- KKR, a leading global investment firm, today released “No Turning Back,” a new Insights piece by Henry McVey, CIO of KKR’s Balance Sheet and Head of Global Macro and Asset Allocation (GMAA). Based on a proprietary survey of nearly 50 Chief Investment Officers (CIOs) who collectively oversee over more than $8 trillion dollars in assets, the report examines how leading insurance companies are navigating and evolving their asset allocation priorities for today’s more volatile interest rate environment. Specifically, McVey notes that allocations to non-traditional inv...
LGI Homes Reports First Quarter 2024 Results
LGI Homes Reports First Quarter 2024 Results THE WOODLANDS, Texas, April 30, 2024 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the three months ended March 31, 2024. First Quarter 2024 Highlights Home sales revenues of $390.9 millionHome closings of 1,083Average sales price per home closed of $360,897Gross margin as a percentage of home sales revenues of 23.4%Adjusted gross margin (non-GAAP) as a percentage of home sales revenues of 25.3%Net income before income taxes of $23.1 millionNet income of $17.1 million, or $0.72 basic EPS and $0....
Broadwind Announces First Quarter 2024 Results Conference Call and Web...
Broadwind Announces First Quarter 2024 Results Conference Call and Webcast Date CICERO, Ill., April 30, 2024 (GLOBE NEWSWIRE) -- Broadwind (Nasdaq: BWEN), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced that it will issue first quarter 2024 results before the market opens on Tuesday, May 14, 2024. A conference call will be held that same day at 11:00 a.m. ET to review the Company’s financial results, discuss recent events and conduct a question-and-answer session. A webcast of the conference call and accompanying presen...
HALLADOR ENERGY COMPANY TO ANNOUNCE FIRST QUARTER 2024 RESULTS
HALLADOR ENERGY COMPANY TO ANNOUNCE FIRST QUARTER 2024 RESULTS TERRE HAUTE, Ind., April 30, 2024 (GLOBE NEWSWIRE) -- Hallador Energy announced today that the company's first quarter 2024 financial results will be released after the market closes on Monday, May 6, 2024. Hallador Energy will host a conference call to discuss its results on Tuesday, May 7, 2024, at 2:00 p.m. EST. The call will be webcast live on the company’s website at under events and will be available for a limited time. Earnings Conference Call and Webcast DetailsPARTICIPANT INFORMATION:Operator Assisted Dial-...
Newron Announces Positive Top-line Results From Potentially Pivotal Ph...
MILAN--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced positive top-line results from its potentially pivotal study 008A, evaluating the safety, tolerability and efficacy of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic including clozapine, but demonstrating an inadequate response to that treatment. The study met it...
Eton Pharmaceuticals Announces Submission to FDA of New Drug Applicati...
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution) - Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product has patent protection through 2043 - DEER PARK, Ill., April 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann...
Playboy Enters into Multiple New China License Agreements
Playboy Enters into Multiple New China License Agreements Represents Major Step by China Joint Venture to Reinvigorate Playboy in China LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, announced that its China joint venture (the “China JV”) has entered into several new licensing agreements with unrelated, third-parties based in China, representing a major step by the China JV to reinvigorate the Playboy brand in China. The series of new agreements is hig...
Gritstone bio Highlights the Durability and Potential Broad Utility of...
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024 -- IgG levels and neutralizing antibodies against variants of concern persisted for at least 12 months, consistent with previous findings -- -- Antigen-specific T cell responses increased in the majority of participants studied, including those living with HIV, after administration of any of the samRNA constructs -- -- Comprehensive data set demonstrates a consistent and strong immunogenicity profile across multiple patient populations in South Af...
Oatly Reports First Quarter 2024 Financial Results
Oatly Reports First Quarter 2024 Financial Results MALMÖ, Sweden, April 30, 2024 (GLOBE NEWSWIRE) -- Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s original and largest oat drink company, today announced financial results for the first quarter ended March 31, 2024. Jean-Christophe Flatin, Oatly’s CEO, commented, “I am pleased to report a solid start to the year. In the first quarter, our brand remained strong, our volumes moved in the right direction, our costs structurally came down while also benefiting from timing, and our business became stronger. We are clearl...
Luckin Coffee Inc. Announces First Quarter 2024 Financial Results
Luckin Coffee Inc. Announces First Quarter 2024 Financial Results First Quarter Net Revenues Increased 41.5% to RMB6,278.1 Million Average Monthly Transacting Customers Increased 103.2% Compared to the Same Period Last Year More than 2,300 Net New Stores Openings; Expanded to More than 18,500 Stores in China BEIJING, April 30, 2024 (GLOBE NEWSWIRE) -- Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced its unaudited financial results for the three months ended March 31, 2024. FIRST QUARTER 2024 HIGHLIGHTS1 Total net revenues in the first quart...
OTC Markets Group Welcomes Osprey Solana Trust to OTCQX
OTC Markets Group Welcomes Osprey Solana Trust to OTCQX NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced (OTCQX: OSOL), an open ended Delaware Grantor Trust that invests substantially all of its assets in SOL, has qualified to trade on the OTCQX® Best Market. Osprey Solana Trust upgraded to OTCQX from the OTCQB® Venture Market. Osprey Solana Trust begins trading today on OTCQX under the symbol “OSOL.” U.S. investors can find current financial disclosure and Real-Time Level 2 q...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.